Immune-related pathologic response assessment upon biopsy material has previously been studied in metastatic melanoma patients receiving anti-PD-1 therapy.22 This study has shown that MPRbx is associated with later radiological response and ultimately with overall survival. Here, PDCD1 is linked to metastatic melanoma.